There are myriad targets that have been deemed undruggable and they "have rankled even the best-funded laboratories over the years," The Scientist says. However, some biotechs are game for taking those impossible targets on — and they appear to be seeing some success. The Scientist notes that one of those companies, Anchor Therapeutics, is working on targeting membrane receptors for Novartis and Ortho-McNeil-Janssen Pharmaceuticals.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.